Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-05-22 00:00:00 ET · period of report 2025-05-20 · accession 0001415889-25-014184 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-22 | 2025-05-20 | SPRY | Scott Kathleen D. | CFO | M - OptEx | $1.50 | +50.0K | 57.4K | +673% | +$75.0K |
| D | 2025-05-22 | 2025-05-20 | SPRY | Scott Kathleen D. | CFO | S - Sale+OE | $14.10 | -50.0K | 7,424 | -87% | -$705.0K |
| D | 2025-05-22 | 2025-05-20 | SPRY | Scott Kathleen D. | CFO | M - OptEx | $0.00 | -50.0K | 752.3K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-20 | M | A | 50,000 | $1.50 | 57,424 | D | — | — | (F1) Includes 2,475 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024. |
| 2 | Common | Common Stock | 2025-05-20 | S | D | 50,000 | $14.10 | 7,424 | D | — | — | (F2) The weighted average sale price for the transaction reported was $14.1033 and the range of prices were between $14.10 and $14.115. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-05-20 | M | D | 50,000 | $0.00 | 752,330 | D | $1.50 · — to 2032-02-29 | 50,000 Common Stock | (F3) Immediately exercisable. |